A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
Status:
Completed
Trial end date:
2020-04-26
Target enrollment:
Participant gender:
Summary
The objective of this study to assess the pharmacokinetics, safety, tolerability and
immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab
in healthy Chinese participants.